To investigate whether PDLIM2 is involved in lung cancer therapeutic responses, we analyzed the 100 patients with known adjuvant treatment (AT) information (divided to 50/50 for PDLIM2 high/low, 96 of them with known information for recurrence-free survival) in the lung cancer cohort GSE3774548. This evidence concerns the gene PDLIM2 and lung carcinoma.